SMARCA4 and non-small cell lung carcinoma: Another NSCLC patient was SMARCA4 deletion combined with ROS1 fusion mutation, and received first-line treatment with pemetrexed combined with carboplatin and ensartinib, with an overall survival of only 3.7 months (19).